|
Gene: FH |
Gene summary for FH |
Gene summary. |
Gene information | Species | Human | Gene symbol | FH | Gene ID | 2271 |
Gene name | fumarate hydratase | |
Gene Alias | FMRD | |
Cytomap | 1q43 | |
Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | A0A0S2Z4C3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2271 | FH | HTA11_347_2000001011 | Human | Colorectum | AD | 1.58e-06 | 3.01e-01 | -0.1954 |
2271 | FH | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.12e-02 | 4.79e-01 | -0.1706 |
2271 | FH | A002-C-205 | Human | Colorectum | FAP | 4.94e-02 | -1.06e-01 | -0.1236 |
2271 | FH | A002-C-116 | Human | Colorectum | FAP | 3.61e-02 | -9.86e-02 | -0.0452 |
2271 | FH | LZE4T | Human | Esophagus | ESCC | 6.44e-07 | 1.96e-01 | 0.0811 |
2271 | FH | LZE7T | Human | Esophagus | ESCC | 4.81e-09 | 7.61e-01 | 0.0667 |
2271 | FH | LZE8T | Human | Esophagus | ESCC | 2.37e-02 | 1.35e-01 | 0.067 |
2271 | FH | LZE22T | Human | Esophagus | ESCC | 6.37e-07 | 2.85e-01 | 0.068 |
2271 | FH | LZE24T | Human | Esophagus | ESCC | 8.09e-10 | 3.08e-01 | 0.0596 |
2271 | FH | LZE21T | Human | Esophagus | ESCC | 3.77e-04 | 2.13e-01 | 0.0655 |
2271 | FH | LZE6T | Human | Esophagus | ESCC | 3.76e-06 | 1.05e-01 | 0.0845 |
2271 | FH | P1T-E | Human | Esophagus | ESCC | 5.79e-10 | 3.64e-01 | 0.0875 |
2271 | FH | P2T-E | Human | Esophagus | ESCC | 3.96e-37 | 8.23e-01 | 0.1177 |
2271 | FH | P4T-E | Human | Esophagus | ESCC | 1.64e-22 | 4.99e-01 | 0.1323 |
2271 | FH | P5T-E | Human | Esophagus | ESCC | 8.71e-43 | 9.22e-01 | 0.1327 |
2271 | FH | P8T-E | Human | Esophagus | ESCC | 6.70e-18 | 2.65e-01 | 0.0889 |
2271 | FH | P9T-E | Human | Esophagus | ESCC | 7.31e-25 | 5.49e-01 | 0.1131 |
2271 | FH | P10T-E | Human | Esophagus | ESCC | 3.37e-23 | 3.57e-01 | 0.116 |
2271 | FH | P11T-E | Human | Esophagus | ESCC | 1.77e-19 | 8.35e-01 | 0.1426 |
2271 | FH | P12T-E | Human | Esophagus | ESCC | 1.01e-25 | 4.56e-01 | 0.1122 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190336312 | Lung | AIS | negative regulation of cellular protein catabolic process | 18/1849 | 75/18723 | 2.89e-04 | 5.40e-03 | 18 |
GO:004586113 | Lung | AIS | negative regulation of proteolysis | 55/1849 | 351/18723 | 3.87e-04 | 6.72e-03 | 55 |
GO:0070371 | Lung | AIS | ERK1 and ERK2 cascade | 52/1849 | 330/18723 | 4.80e-04 | 7.95e-03 | 52 |
GO:003530313 | Lung | AIS | regulation of dephosphorylation | 25/1849 | 128/18723 | 6.76e-04 | 1.01e-02 | 25 |
GO:00426921 | Lung | AIS | muscle cell differentiation | 58/1849 | 384/18723 | 7.00e-04 | 1.03e-02 | 58 |
GO:003806611 | Lung | AIS | p38MAPK cascade | 14/1849 | 55/18723 | 7.09e-04 | 1.04e-02 | 14 |
GO:000616313 | Lung | AIS | purine nucleotide metabolic process | 59/1849 | 396/18723 | 8.91e-04 | 1.20e-02 | 59 |
GO:0070372 | Lung | AIS | regulation of ERK1 and ERK2 cascade | 48/1849 | 309/18723 | 1.06e-03 | 1.38e-02 | 48 |
GO:007252113 | Lung | AIS | purine-containing compound metabolic process | 61/1849 | 416/18723 | 1.10e-03 | 1.42e-02 | 61 |
GO:190305112 | Lung | AIS | negative regulation of proteolysis involved in cellular protein catabolic process | 15/1849 | 64/18723 | 1.17e-03 | 1.49e-02 | 15 |
GO:0007626 | Lung | AIS | locomotory behavior | 31/1849 | 179/18723 | 1.39e-03 | 1.70e-02 | 31 |
GO:00605371 | Lung | AIS | muscle tissue development | 58/1849 | 403/18723 | 2.22e-03 | 2.37e-02 | 58 |
GO:004801611 | Lung | AIS | inositol phosphate-mediated signaling | 13/1849 | 55/18723 | 2.25e-03 | 2.39e-02 | 13 |
GO:003090011 | Lung | AIS | forebrain development | 55/1849 | 379/18723 | 2.37e-03 | 2.48e-02 | 55 |
GO:003530413 | Lung | AIS | regulation of protein dephosphorylation | 18/1849 | 90/18723 | 2.76e-03 | 2.76e-02 | 18 |
GO:0019932 | Lung | AIS | second-messenger-mediated signaling | 46/1849 | 312/18723 | 3.79e-03 | 3.52e-02 | 46 |
GO:003530812 | Lung | AIS | negative regulation of protein dephosphorylation | 9/1849 | 34/18723 | 4.68e-03 | 4.09e-02 | 9 |
GO:00511461 | Lung | AIS | striated muscle cell differentiation | 42/1849 | 283/18723 | 4.88e-03 | 4.24e-02 | 42 |
GO:19007441 | Lung | AIS | regulation of p38MAPK cascade | 11/1849 | 47/18723 | 5.19e-03 | 4.46e-02 | 11 |
GO:20000598 | Lung | AIS | negative regulation of ubiquitin-dependent protein catabolic process | 11/1849 | 48/18723 | 6.14e-03 | 4.98e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa01200 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa00620 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa00020 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
hsa05211 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
hsa012001 | Colorectum | AD | Carbon metabolism | 55/2092 | 115/8465 | 5.53e-08 | 8.42e-07 | 5.37e-07 | 55 |
hsa006201 | Colorectum | AD | Pyruvate metabolism | 28/2092 | 47/8465 | 3.71e-07 | 5.41e-06 | 3.45e-06 | 28 |
hsa000201 | Colorectum | AD | Citrate cycle (TCA cycle) | 20/2092 | 30/8465 | 1.43e-06 | 1.77e-05 | 1.13e-05 | 20 |
hsa052111 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
hsa006202 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa000202 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa012002 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa006203 | Colorectum | SER | Pyruvate metabolism | 22/1580 | 47/8465 | 9.62e-06 | 1.33e-04 | 9.67e-05 | 22 |
hsa000203 | Colorectum | SER | Citrate cycle (TCA cycle) | 16/1580 | 30/8465 | 2.06e-05 | 2.74e-04 | 1.99e-04 | 16 |
hsa012003 | Colorectum | SER | Carbon metabolism | 40/1580 | 115/8465 | 2.77e-05 | 3.41e-04 | 2.47e-04 | 40 |
hsa012006 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa012007 | Colorectum | FAP | Carbon metabolism | 38/1404 | 115/8465 | 1.04e-05 | 1.44e-04 | 8.76e-05 | 38 |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FH | SNV | Missense_Mutation | novel | c.345G>T | p.Lys115Asn | p.K115N | P07954 | protein_coding | tolerated(0.1) | benign(0.044) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FH | SNV | Missense_Mutation | c.848N>C | p.Leu283Ser | p.L283S | P07954 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FH | SNV | Missense_Mutation | novel | c.442C>G | p.Gln148Glu | p.Q148E | P07954 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
FH | SNV | Missense_Mutation | c.778N>G | p.Thr260Ala | p.T260A | P07954 | protein_coding | tolerated(0.77) | benign(0) | TCGA-E9-A1RC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
FH | insertion | Nonsense_Mutation | novel | c.467_468insAGGTCACTAAACCCTGCCTGCATTCCAGGCACTGTATTTC | p.Ile157GlyfsTer3 | p.I157Gfs*3 | P07954 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
FH | SNV | Missense_Mutation | novel | c.625C>T | p.Pro209Ser | p.P209S | P07954 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FH | SNV | Missense_Mutation | rs778578307 | c.227N>T | p.Thr76Met | p.T76M | P07954 | protein_coding | tolerated(0.05) | benign(0.026) | TCGA-JW-A69B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FH | SNV | Missense_Mutation | c.359N>A | p.Ile120Lys | p.I120K | P07954 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FH | SNV | Missense_Mutation | rs755449276 | c.953N>G | p.His318Arg | p.H318R | P07954 | protein_coding | tolerated(0.08) | benign(0.145) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
FH | SNV | Missense_Mutation | c.307N>A | p.Ala103Thr | p.A103T | P07954 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2271 | FH | CLINICALLY ACTIONABLE, ENZYME, DNA REPAIR | DIETHYLDITHIOCARBAMATE | DITIOCARB | 1850448 |
Page: 1 |